CA-BROWSERSTACK
22.11.2021 11:58:13 CET | Business Wire | Press release
BrowserStack , the world's leading software testing platform, today announced support for Selenium 4 on BrowserStack Automate, its automation testing product. Released in October 2021, Selenium 4 comes with a host of new features, which BrowserStack Automate supports out-of-the-box (no special installation or configuration required).
"The BrowserStack Open Source Program Team has collaborated with the Selenium project and contributed extensively to Selenium 4 over the last two years, such as working on Selenium Grid rewrite," said David Burns, Head of Open Source at BrowserStack and Core Contributor to Selenium. "We also contributed code to key parts like the Observability features, collaborated on supported languages in Selenium Client bindings, and our interns built the first version of the new Selenium Grid UI while improving the GraphQL support."
One of the most exciting updates is the introduction of 'relative locators', which allows developers to locate page elements based on their relative location to the other, particularly helpful when dealing with complex DOM structures. In addition, with support for its BiDi APIs, developers can monitor browser console logs, listen to JS Exceptions and intercept, validate or modify network requests through the NetworkInterceptor.
"The capabilities of Selenium 4 move beyond just browser functionality. Automate's support for all new features of Selenium 4 ensures users get maximum value out of our platform," said Nakul Aggarwal, Co-founder, and CTO of BrowserStack. "We're committed to working closely with and giving back to the open source community."
About BrowserStack
BrowserStack is the world's leading software testing platform powering over two million tests every day across 15 global data centers. BrowserStack helps Tesco, Shell, NVIDIA, Discovery, Wells Fargo, and over 50,000 customers deliver quality software at speed by moving testing to their Cloud. BrowserStack's platform provides instant access to 3,000+ real mobile devices and browsers on a highly reliable cloud platform that effortlessly scales as testing needs grow.
Founded in 2011, BrowserStack is a privately held company backed by Accel, Bond Capital, and Insight Partners. For more information, visit browserstack.com or follow on Twitter @browserstack .
About Selenium
Selenium is an umbrella open-source project for a suite of tools for web browser automation. Developed in 2004, there is now a large ecosystem of open source projects built around Selenium. For more information, visit selenium.dev or follow on Twitter @SeleniumHQ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211122006110/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Philip Morris International and Maestro Andrea Bocelli Present “Believe. Further”29.6.2026 12:00:00 CEST | Press release
A new platform for dialogue on progress, reflecting a mutual commitment to advancing positive change Philip Morris International (PMI) (NYSE: PM) and Maestro Andrea Bocelli today presented “Believe. Further”, a multi-year platform designed to engage audiences in a broader conversation on progress and positive change. The launch took place at the Torre dell’Arsenale in Venice, where heritage and forward movement meet, a fitting setting for two voices on a similar path. What do you do when the world has already decided what you are? “Believe. Further” begins from that question. It is built around a shared belief in progress and a shared conviction in transformation. At a time when science and technology allow better choices, it brings together two voices that, independently and in parallel, are undergoing a change in motion, and invites the beginning of a different conversation with society at large. Maestro Bocelli’s journey has been defined by belief. From the beginnings of his career
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom